Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 10, pp 1359–1367 | Cite as

High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection

  • Jie Hu
  • Yang Xu
  • Zao-Zhuo Shen
  • Zheng Wang
  • Qing Lu
  • Guo-Huan Yang
  • Zheng-Bin Ding
  • Jia Fan
  • Jian Zhou
Original Paper

Abstract

Purpose

To evaluate the prognosis value of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) in alpha-fetoprotein (AFP)-negative hepatocellular carcinoma (HCC) patients after curative resection.

Methods

Tumor tissue microarrays (TMAs) were used to detect the expressions of VEGF and PD-ECGF in consecutive 162 AFP-negative HCC patients undergoing curative resection between 1997 and 2000 in our institute. Clinicopathologic data for these patients were evaluated. The prognostic significance was assessed using Kaplan–Meier survival estimates and log-rank tests. Multivariate study with Cox’s proportional hazard model was used to evaluate the prognosis-related aspects.

Results

The positive rates of VEGF and PD-ECGF in tumor tissues were 59.9% (97/162) and 62.3% (101/162), respectively. Univariate analysis showed that VEGF and PD-ECGF were prognostic factors for relapse-free survival (P = 0.034 and P = 0.033, respectively). Multivariate analyses demonstrated that the co-index (VEGF/PD-ECGF) was an independent prognostic factor for overall survival and relapse-free survival (P = 0.002 and P = 0.000, respectively).

Conclusion

The co-index of VEGF and PD-ECGF is a promising independent predictor for recurrence and survival of AFP-negative HCC patients after curative resection.

Keywords

Hepatocellular carcinoma Vascular endothelial growth factor Platelet-derived endothelial cell growth factor Prognosis Tissue microarrays 

Abbreviations

HCC

Hepatocellular carcinoma

AFP

Alpha-fetoprotein

HBV

Hepatitis B virus

HCV-Ab

Hepatitis C virus antibody

VEGF

Vascular endothelial growth factor

PD-ECGF

Platelet-derived endothelial cell growth factor

TMAs

Tissue microarrays

TNM

Tumor-node metastasis

TACE

Transcatheter arterial chemoembolization

OS

Overall survival

RFS

Relapse-free survival

Notes

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (No. 30873039), Shanghai Science and Technology Development Funds (No. 07JC14010, 06QA14012, 07SP07003) and National Hi-Tech Research and Development Program of China (No.2007AA02Z479).

Conflict of interest statement

This is an original work by all the authors and no previous presentations, reports or publications contain any material that appears in the article. We certify that no actual or potential conflict of interest in relation to this article exists.

Supplementary material

432_2009_577_MOESM1_ESM.doc (38 kb)
Supplementary material 1 (DOC 38 kb)

References

  1. Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300. doi: 10.1200/JCO.2005.01.3441 CrossRefPubMedGoogle Scholar
  2. Baron RL, Brancatelli G (2004) Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 127:S133–S143. doi: 10.1053/j.gastro.2004.09.027 CrossRefPubMedGoogle Scholar
  3. Berse B, Brown LF, Van de Water L et al (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211–220PubMedGoogle Scholar
  4. Bosch FX, Ribes J, Cleries R et al (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191–211. doi: 10.1016/j.cld.2004.12.009 CrossRefPubMedGoogle Scholar
  5. Chao Y, Li CP, Chau GY et al (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10:355–362. doi: 10.1245/ASO.2003.10.002 CrossRefPubMedGoogle Scholar
  6. Chen G, Lin W, Shen F et al (2006) Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 101:1797–1803. doi: 10.1111/j.1572-0241.2006.00647.x CrossRefPubMedGoogle Scholar
  7. Daniele B, Bencivenga A, Megna AS et al (2004) Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127:S108–S112. doi: 10.1053/j.gastro.2004.09.023 CrossRefPubMedGoogle Scholar
  8. Deli G, Jin CH, Mu R et al (2005) Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 11:960–963PubMedGoogle Scholar
  9. Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 7:462–503. doi: 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E CrossRefPubMedGoogle Scholar
  10. Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:C1358–C1366PubMedGoogle Scholar
  11. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18PubMedGoogle Scholar
  12. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934PubMedGoogle Scholar
  13. Guo L, Kuroda N, Toi M et al (2001) Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis. Oncol Rep 8:871–876PubMedGoogle Scholar
  14. Haraguchi M, Miyadera K, Uemura K et al (1994) Angiogenic activity of enzymes. Nature 368:198. doi: 10.1038/368198a0 CrossRefPubMedGoogle Scholar
  15. Hu L, Lau SH, Tzang CH et al (2004) Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23:298–302. doi: 10.1038/sj.onc.1207150 CrossRefPubMedGoogle Scholar
  16. Johnson PJ (2001) The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5:145–159. doi: 10.1016/S1089-3261(05)70158-6 CrossRefPubMedGoogle Scholar
  17. Li XM, Tang ZY, Qin LX et al (1999) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 18:511–517PubMedGoogle Scholar
  18. Li D, Mallory T, Satomura S (2001) AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 313:15–19. doi: 10.1016/S0009-8981(01)00644-1 CrossRefPubMedGoogle Scholar
  19. Liu WC, Lim JH, Park CK et al (2003) Poor sensitivity of sonography in detection of hepatocellular carcinoma in advanced liver cirrhosis: accuracy of pretransplantation sonography in 118 patients. Eur Radiol 13:1693–1698. doi: 10.1007/s00330-002-1814-3 CrossRefPubMedGoogle Scholar
  20. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390. doi: 10.1056/NEJMoa0708857 CrossRefPubMedGoogle Scholar
  21. Mattern J, Koommagi R, Volm M (1999) Biological characterization of subgroups of squamous cell lung carcinomas. Clin Cancer Res 5:1459–1463PubMedGoogle Scholar
  22. Ng IO, Poon RT, Lee JM et al (2001) Microvessel density, vascular endothelial growth factor and its receptors Flt-1and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116:838–845. doi: 10.1309/FXNL-QTN1-94FH-AB3A CrossRefPubMedGoogle Scholar
  23. Nolte W, Hartmann H, Ramadori G et al (1995) Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 103:63–74CrossRefPubMedGoogle Scholar
  24. Park JH, Koh KC, Choi MS et al (2006) Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg 192:29–33. doi: 10.1016/j.amjsurg.2005.11.010 CrossRefPubMedGoogle Scholar
  25. Peng SY, Chen WJ, Lai PL et al (2004) High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 112:44–50. doi: 10.1002/ijc.20279 CrossRefPubMedGoogle Scholar
  26. Poon RT, Ng IO, Lau C et al (2001) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233:227–235. doi: 10.1097/00000658-200102000-00012 CrossRefPubMedGoogle Scholar
  27. Poon RT, Ho JW, Tong CS et al (2004) Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91:1354–1360. doi: 10.1002/bjs.4594 CrossRefPubMedGoogle Scholar
  28. Schmitt M, Horbach A, Kubitz R et al (2004) Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 41:274–283. doi: 10.1016/j.jhep.2004.04.035 CrossRefPubMedGoogle Scholar
  29. Shah SA, Cleary SP, Wei AC et al (2007) Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141:330–339. doi: 10.1016/j.surg.2006.06.028 CrossRefPubMedGoogle Scholar
  30. Shiraki K, Takase K, Tameda Y et al (1995) A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22:802–807CrossRefPubMedGoogle Scholar
  31. Taketa K, Endo Y, Sekiya C et al (1993) A collaborative study for the evaluation of lectinreactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 53:5419–5423PubMedGoogle Scholar
  32. Tang ZY, Ye SL, Liu YK et al (2004) A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130:187–196. doi: 10.1007/s00432-003-0511-1 CrossRefPubMedGoogle Scholar
  33. Toi M, Matsumoto T, Bando H et al (2001) Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2:667–673. doi: 10.1016/S1470-2045(01)00556-3 CrossRefPubMedGoogle Scholar
  34. Tralhao JG, Dagher I, Lino T et al (2004) Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol 33:746–751. doi: 10.1016/j.ejso.2006.11.015 Google Scholar
  35. Uematsu S, Higashi T, Nouso K et al (2005) Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20:583–588. doi: 10.1111/j.1440-1746.2005.03726.x CrossRefPubMedGoogle Scholar
  36. Valls C, Cos M, Figueras J et al (2004) Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dual-phase helical CT. AJR Am J Roentgenol 182:1011–1017PubMedGoogle Scholar
  37. Yang Y, Nagano H, Ota H et al (2007) Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 141:196–202. doi: 10.1016/j.surg.2006.06.033 CrossRefPubMedGoogle Scholar
  38. Yang GH, Fan J, Xu Y et al (2008) Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 13:1155–1165. doi: 10.1634/theoncologist.2008-0081 CrossRefPubMedGoogle Scholar
  39. Yoshiji H, Kuriyama S, Hicklin DJ et al (1999) KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30:1179–1186. doi: 10.1002/hep.510300509 CrossRefPubMedGoogle Scholar
  40. Zhou J, Tang ZY, Fa J et al (2000) Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 126:57–61. doi: 10.1007/s004320050009 CrossRefPubMedGoogle Scholar
  41. Zhu AX (2008) Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112:250–259CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Jie Hu
    • 1
  • Yang Xu
    • 1
  • Zao-Zhuo Shen
    • 1
  • Zheng Wang
    • 1
  • Qing Lu
    • 1
  • Guo-Huan Yang
    • 1
  • Zheng-Bin Ding
    • 1
  • Jia Fan
    • 1
    • 2
  • Jian Zhou
    • 1
    • 2
  1. 1.Key Laboratory for Carcinogenesis & Cancer Invasion, The Chinese Ministry of Education, Liver Cancer Institute, Zhong Shan Hospital and Shanghai Medical SchoolFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Institute of Biomedical SciencesFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations